Incyte Appoints Steven H. Stein, MD as Chief Medical Officer

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte's extensive oncology portfolio.

"We are very fortunate to have attracted someone with Steven's track record of success and strong hematology oncology expertise to lead our clinical team"
He will join the executive management team of Incyte, and report to Richard S. Levy, MD, Executive Vice President and Chief Drug Development Officer.

"We are very fortunate to have attracted someone with Steven's track record of success and strong hematology oncology expertise to lead our clinical team," said Rich Levy, MD, EVP and Chief Drug Development Officer at Incyte. "Steven's experience in clinical development and his regulatory knowledge will be critical in helping Incyte achieve its vision of becoming one of the leading global oncology companies."

"I am tremendously excited and privileged to be joining Incyte," added Steven Stein, MD, Incyte's Chief Medical Officer. "This is an exciting time in the drug development space, and with its innovative products and talented team, I am eager to get started at Incyte."

Dr. Stein's primary responsibility at Novartis was leading Novartis Oncology's North American medical/scientific activities, including the planning, resource allocation and execution of registration and non-registration studies. He was also responsible for the Medical Sciences & Health Outcomes function, which included the Scientific Communications, Medical Information and Health Economics and Outcomes Research groups. Dr. Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care.

Dr. Stein earned his MD from the University of Witwatersrand in Johannesburg, South Africa. He has authored more than 100 scientific papers and presentations and is also an active member of several professional and scientific societies and academic committees.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Contacts

Incyte Corporation
Michael Booth, DPhil
Vice President, Investor Relations
302-498-5914

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.